中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

29 records (took 0.018 seconds)

    Anti-human ovarian cancer immunotoxins and methods of use thereof
    2.
    发明授权
    Anti-human ovarian cancer immunotoxins and methods of use thereof 失效
    抗人卵巢癌免疫毒素及其使用方法

    公开(公告)号：US4956453A

    公开(公告)日：1990-09-11

    申请号：US69720

    申请日：1987-07-06

    Applicant: Michael J. Bjorn ,  Arthur E. Frankel ,  Walter J. Laird ,  David B. Ring ,  Jeffrey L. Winkelhake

    Inventor： Michael J. Bjorn ,  Arthur E. Frankel ,  Walter J. Laird ,  David B. Ring ,  Jeffrey L. Winkelhake

    IPC: A61K38/00 ,  A61K47/48 ,  C07K16/30

    CPC classification number: C07K16/30 ,  A61K47/48638 ,  A61K38/00 ,  Y10S424/804 ,  Y10S424/807 ,  Y10S514/885 ,  Y10S530/808 ,  Y10S530/861 ,  Y10S530/864 ,  Y10S530/866

    Abstract: Immunotoxins comprising a cytotoxic moiety and an antigen binding portion selected from the group consisting of Fab, Fab' and F(ab').sub.2 fragments of a monoclonal antibody, which binds to human ovarian cancer tissue, having one of the following capabilities are claimed: cytotoxic ID.sub.50 of about 10 nM or less against human ovarian cancer cells, retardation of human ovarian cancer tumor growth in mammals, or extension of survival of a mammal carrying a human ovarian cancer tumor. Antigens or epitopes to which the monoclonal antibodies bind are identified and characterize the immunotoxins. In a preferred embodiment an immunotoxin comprising at least an antigen binding portion of a monoclonal antibody, which binds to human transferrin receptor, but does not block binding of transferrin to the receptor, is described and claimed. Immunotoxin comprising the F(ab').sub.2 region of the antitransferrin monoclonal antibody are also claimed.Methods of killing human ovarian cancer cells, retarding the growth of human ovarian cancer tumors in mammals and extending the survial of mammals carrying human ovarian cancer tumors are claimed.

    Abstract translation: 要求具有下列能力之一的包含细胞毒素部分和选自Fab，Fab'和F（ab'）2结合部分的单克隆抗体结合人卵巢癌组织的抗原结合部分的免疫毒素： 对人卵巢癌细胞约10nM或更少的细胞毒性ID50，哺乳动物中人卵巢癌肿瘤生长的延迟或携带人卵巢癌肿瘤的哺乳动物的存活的延长。 识别单克隆抗体结合的抗原或表位，并表征免疫毒素。 在优选的实施方案中，描述并要求保护包含至少结合人转铁蛋白受体但不阻断转铁蛋白与受体结合的单克隆抗体的抗原结合部分的免疫毒素。 还要求保护包含抗转铁蛋白单克隆抗体的F（ab'）2区的免疫毒素。 要求杀死人类卵巢癌细胞的方法，延缓哺乳动物中人卵巢癌肿瘤的生长并延长携带人卵巢癌肿瘤的哺乳动物的存活。

    P. obtusus strain
    7.
    发明授权
    P. obtusus strain 失效
    鹿角us属

    公开(公告)号：US4569915A

    公开(公告)日：1986-02-11

    申请号：US583166

    申请日：1984-02-24

    Applicant: David B. Ring

    Inventor： David B. Ring

    IPC: C12N9/04 ,  C12N1/14 ,  C12P19/22 ,  C12R1/645

    CPC classification number: C12N9/0006 ,  C12R1/645 ,  Y10S435/911

    Abstract: A P. obtusus strain AU124 having the identifying characteristics of NRRL No. 15595, the strain produces high levels of pyranose-2-oxidase.

    Abstract translation: 具有NRRL No.15595的鉴定特征的P. obtusus菌株AU124，该菌株产生高水平的吡喃糖-2-氧化酶。

    Inhibitors of glycogen synthase 3 kinase
    8.
    发明授权
    Inhibitors of glycogen synthase 3 kinase 失效
    糖原合成酶3激酶抑制剂

    公开(公告)号：US6153618A

    公开(公告)日：2000-11-28

    申请号：US948887

    申请日：1997-10-10

    Applicant: Peter Schultz ,  David B. Ring ,  Stephen D. Harrison ,  Andrew M. Bray

    Inventor： Peter Schultz ,  David B. Ring ,  Stephen D. Harrison ,  Andrew M. Bray

    IPC: C07D473/16 ,  A61K31/52

    CPC classification number: C07D473/16

    Abstract: Compounds of formula 1: ##STR1## wherein R.sub.1 is alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl, substituted with 0-3 substituents selected from lower alkyl, halo, hydroxy, lower alkoxy, amino, lower alkyl-amino, and nitro;R.sub.2 is hydroxy, amino, or lower alkoxy;R.sub.3 is H, lower alkyl, lower acyl, lower alkoxy-acyl, or amnino-acyl;R.sub.4 is H or lower alkyl; and pharmaceutically acceptable salts and esters thereof; are effective inhibitors of GSK3.

    Abstract translation: 式1化合物：其中R 1是被0-3个选自低级烷基，卤素，羟基，低级烷氧基，氨基，低级烷基 - 氨基和硝基的取代基取代的烷基，环烷基，芳基，芳烷基，杂芳基或杂芳烷基。 R2是羟基，氨基或低级烷氧基; R3是H，低级烷基，低级酰基，低级烷氧基 - 酰基或氨基 - 酰基; R4是H或低级烷基; 及其药学上可接受的盐和酯; 是GSK3的有效抑制剂。

    Antigen-binding sites of antibody molecules specific for cancer antigens
    9.
    发明授权
    Antigen-binding sites of antibody molecules specific for cancer antigens 失效
    针对癌症抗原的抗体分子的抗原结合位点

    公开(公告)号：US6054561A

    公开(公告)日：2000-04-25

    申请号：US483749

    申请日：1995-06-07

    Applicant: David B. Ring

    Inventor： David B. Ring

    IPC: C07K16/32 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30

    CPC classification number: C07K16/32 ,  C07K2317/24 ,  C07K2317/622

    Abstract: Novel compositions are provided that are derived from antigen-binding sites of immunoglobulins having affinity for cancer antigens. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human tumor cell expressing an antigen selected from the group consisting of high molecular weight mucins bound by 2G3 and 369F10, c-erbB-2 tumor antigen, an approximately 42 kD glycoprotein, an approximately 55 kD glycoprotein, and the approximately 40, 60, 100 and 200 kD antigens bound by 113F1. A number of synthetic molecules are provided that include CDR and FR regions derived from same or different immunoglobulin moieties. Also provided are single chain polypeptides wherein V.sub.H and V.sub.L domains are attached by a single polypeptide linker. The sFv molecules can include ancillary polypeptide moieties which can be bioactive, or which provide a site of attachment for other useful moieties. The compositions are useful in specific binding assays, affinity purification schemes, drug or toxin targeting, imaging, and genetic or immunological therapeutics for various cancers. The invention thus provides novel polypeptides, the DNAs encoding those polypeptides, expression cassettes comprising those DNAs, and methods of inducing the production of the polypeptides.

    Abstract translation: 提供衍生自对癌抗原具有亲和力的免疫球蛋白的抗原结合位点的新型组合物。 该组合物表现出能够特异性结合表达选自由2G3和369F10，c-erbB-2肿瘤抗原，约42kD糖蛋白结合的高分子量粘蛋白的抗原的抗原分子的免疫学结合特性 约55kD的糖蛋白，以及由113F1结合的约40,60,100和200kD的抗原。 提供了许多合成分子，其包括衍生自相同或不同免疫球蛋白部分的CDR和FR区。 还提供了单链多肽，其中VH和VL结构域通过单个多肽接头连接。 sFv分子可以包括可以是生物活性的辅助多肽部分，或提供其它有用部分的连接位点。 组合物可用于特异性结合测定，亲和纯化方案，靶向药物或毒素，成像以及各种癌症的遗传或免疫治疗。 因此，本发明提供了新的多肽，编码那些多肽的DNA，包含那些DNA的表达盒，以及诱导多肽的产生的方法。

Patent Agency Ranking